Trials / Completed
CompletedNCT00102531
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Phase Ib/IIa Study of SLIT Cisplatin by Inhalation in the Treatment of Patients Wtih Relapsed/Progressive Osteosarcoma Metastatic to the Lung
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- Insmed Incorporated · Industry
- Sex
- All
- Age
- 13 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin liposomal |
Timeline
- Start date
- 2005-01-12
- Primary completion
- 2008-03-01
- Completion
- 2008-03-17
- First posted
- 2005-01-31
- Last updated
- 2017-08-01
- Results posted
- 2017-08-01
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00102531. Inclusion in this directory is not an endorsement.